The Cooper Companies, Inc.
NASDAQ•COO
CEO: Mr. Albert G. White III
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1983-01-21
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Contact Information
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, 94583, United States
925-460-3600
Market Cap
$11.94B
P/E (TTM)
30.0
39.9
Dividend Yield
--
52W High
$89.83
52W Low
$58.89
52W Range
Rank35Top 29.9%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$1.02B+0.00%
4-Quarter Trend
EPS
$0.66+0.00%
4-Quarter Trend
FCF
$158.70M+0.00%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Net Sales Growth Strong Quarterly net sales reached $1,024.1M, marking an 8% increase compared to prior period sales of $964.7M.
Net Income Rises Net income grew to $130.8M from $104.3M, driving diluted EPS to $0.66 from $0.52 previously.
Operating Cash Flow Boost Cash provided by operating activities increased significantly to $260.9M, up from $190.6M in the prior period.
CooperVision Sales Surge CooperVision net sales grew 8% to $695.1M, led by 10% growth in Toric and multifocal products.
Risk Factors
UK Tax Dispute Loss Potential Adverse UK FTT payroll tax decision supports HMRC; potential loss estimated up to £71.7M plus interest.
Increased Short-Term Borrowing Total current liabilities rose sharply to $1,595.7M, driven by $620.7M in short-term debt outstanding.
Global Market Uncertainties Macroeconomic instability, international conflicts, and regulatory changes pose risks to future sales and cash flow performance.
Intangible Asset Exposure Management must continually evaluate goodwill and intangible assets for potential impairment risks across operations.
Outlook
Debt Maturity Extended Amendment No. 3 extended maturity for $950.0M of 2021 Term Loan debt to February 2031.
Share Repurchase Activity Repurchased $92.5M in common stock during the quarter; $873.9M remains authorized under the program.
Liquidity Position Stable Current cash and expected operating cash flow deemed sufficient to meet needs for at least 12 months.
CooperVision Expansion Focus Focus remains on global penetration of recently introduced silicone hydrogel products, including MiSight lens approvals.
Peer Comparison
Revenue (TTM)
$22.44B
$17.76B
$11.99B
Gross Margin (Latest Quarter)
98.3%
86.7%
68.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ILMN | $24.66B | 29.2 | 34.0% | 37.6% |
| WST | $22.81B | 42.8 | 17.9% | 7.7% |
| HOLX | $16.97B | 31.4 | 11.0% | 27.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.7%
Moderate Growth
4Q Net Income CAGR
14.3%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Jun 4, 2026
EPS:$1.10
|Revenue:$1.05B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data